Rabbit polyclonal anti-thymocyte globulin that depletes T cells to prevent rejection and GVHD.
Rabbit polyclonal anti-thymocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, producing immunosuppression to prevent rejection and GVHD.
NO
INDIRECT
Thymoglobulin does not target HLA-C; it binds multiple T-cell antigens (e.g., CD2/CD3/CD4/CD8) and depletes T cells via complement-dependent cytotoxicity, ADCC, and apoptosis.
AMG 451; a subcutaneous afucosylated IgG1 monoclonal antibody that targets OX40 (CD134), blocking OX40/OX40L costimulatory signaling and depleting OX40-positive activated T cells via ADCC to reduce sustained T-cell activation and type 2 inflammation.
Afucosylated IgG1 monoclonal antibody targeting OX40 (CD134) that blocks OX40/OX40L costimulatory signaling and depletes OX40-positive activated T cells via enhanced ADCC, reducing sustained T-cell activation and type 2 inflammatory responses.
YES
DIRECT
Antibody binds OX40 on activated T cells and, via its afucosylated IgG1 Fc, engages FcγRIIIa on NK cells to drive enhanced ADCC, leading to lysis/apoptosis of OX40+ cells (with possible ADCP by myeloid cells).
Glycoengineered type II humanized anti-CD20 monoclonal antibody that depletes CD20+ B cells via enhanced antibody-dependent cellular cytotoxicity/phagocytosis and direct cell death, with limited complement activation.
Glycoengineered humanized IgG1 type II anti‑CD20 mAb that binds CD20 on B cells and depletes CD20+ cells via enhanced FcγRIIIa‑mediated ADCC and antibody‑dependent phagocytosis, plus direct caspase‑independent cell death, with minimal complement activation.
YES
DIRECT
Binds CD20 on B cells and depletes them via enhanced Fc-gamma RIIIa–mediated ADCC and antibody-dependent phagocytosis, plus direct caspase-independent cell death (minimal complement).
Glycoengineered type II humanized anti-CD20 monoclonal antibody that depletes CD20+ B cells via enhanced antibody-dependent cellular cytotoxicity/phagocytosis and direct cell death, with limited complement activation.
Glycoengineered humanized IgG1 type II anti‑CD20 mAb that binds CD20 on B cells and depletes CD20+ cells via enhanced FcγRIIIa‑mediated ADCC and antibody‑dependent phagocytosis, plus direct caspase‑independent cell death, with minimal complement activation.
NO
INDIRECT
Obinutuzumab binds CD20 on B cells; its Fc engages FcγRIIIa (CD16a) on NK cells/macrophages to activate ADCC and phagocytosis of CD20+ cells. CD16a-expressing effector cells are engaged, not killed.
A bispecific monoclonal antibody T‑cell engager (REGN5458) that binds BCMA on myeloma cells and CD3 on T cells to redirect CD3+ T cells to kill BCMA+ malignant plasma cells.
Linvoseltamab (REGN5458) is a bispecific antibody that binds BCMA on multiple myeloma cells and CD3 on T cells, redirecting and activating CD3+ T cells to form cytolytic synapses and kill BCMA-expressing malignant plasma cells.
YES
DIRECT
Bispecific antibody links CD3+ T cells to BCMA+ cells, forming cytolytic synapses and triggering T-cell–mediated killing via perforin/granzyme-induced apoptosis of BCMA-expressing cells.